Skip to main content

Relapsing-Remitting Multiple Sclerosis (MS) Market Size, Trends, Challenges, Segmentation with Forecast 2023

The Global “Relapsing-Remitting Multiple Sclerosis (MS) Market is expected to register a CAGR of 3.1% during the forecast period of 2019 to 2025” and held a value of USD 4,976 million in 2018.
Market Overview
Relapsing-Remitting Multiple Sclerosis Market is characterized by attacks of new or increasing neurologic symptoms. These attacks are also called relapses or exacerbations and are followed by periods of partial or complete recovery. Approximately 85% of people with MS are initially diagnosed with relapsing remitting MS.
The growth of the global Relapsing-Remitting Multiple Sclerosis Market is boosted by various factors such as rising research in the multiple sclerosis treatment fields and increasing innovations by significant players. However, the stringent regulations and high cost of drugs are likely to curb the growth of the global relapsing-remitting MS market.
Market Segmentation
The global Relapsing-Remitting Multiple Sclerosis Market has been segmented based on treatment, route of administration, and end user.
based on treatment, has been divided into immunomodulating drugs, Nrf2 activators, interferons, and others. The immunomodulating drugs segment is likely to be the largest during the review period due to the growing advantages of this drug type in comparison to others. The Nrf2 activators segment is predicted to be the fastest-growing due to the increasing awareness and research in the market.
based on the route of administration, into oral and intravenous. The oral segment is expected to hold the majority share of the market owing to the increasing efficiency rates of this mechanism. The intravenous segment is expected to be the fastest-growing due to the increased awareness about this route of administration.
The end users of the market are hospitals, clinics, and others. The hospitals segment is expected to hold the largest share of the market due to the increasing number of hospitals. The clinics segment is expected to be the fastest growing owing to the increased preference of medical professionals.
Major Market Key Players
Several market players currently dominate the global relapsing-remitting MS market. The key players are involved in product launches and strategic collaborations to strengthen their market positions.
Some of the key players in the global Competitive market are –
Glenmark Pharmaceuticals (India)
Eisai Co.Ltd (Japan)
Biogen (US)
Merck KGaA (US)
Sanofi Genzyme (US)
Novartis AG (Switzerland)
Teva Pharmaceutical Industries Ltd (Israel).
Market Drivers
  • Increasing research initiatives
  • Rising need for treatment of relapsing-remitting MS
  • High prevalence of MS
  • Increasing product launches
  • Growing awareness regarding the severity of this form of MS
Regional Analysis
The Relapsing-Remitting Multiple Sclerosis Market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the upcoming research activities by key players. The market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing pool of patient population suffering from relapsing-remitting MS, the market in Asia-Pacific is expected to be the fastest-growing. The Market in the Middle East & Africa has been divided into the Middle East and Africa.
About Market Research Future: MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Market Research Future
+1 646 845 9312
Labels:

Comments

Post a Comment

Popular posts from this blog

Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Growth Drivers, Restraints and Opportunities, Forecast To 2025

Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Size Research Report: Information by Treatment (Drug Class (Mitogen-Activated Protein Kinases (MAPK) Inhibitors, Tyrosine Kinase Inhibitors, Autotaxin Inhibitors, Others), Oxygen Therapy, Lung Transplant, Others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025 Global  Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Size  Insights 2020 provides a unique tool for evaluating the Market, highlighting opportunities, and supporting strategic and tactical decision-making. This report recognizes that in this rapidly-evolving and competitive environment, up-to-date Marketing information is essential to monitor performance and make critical decisions for growth and profitability. Some of the key players operating for the global market analysis are  Boehringer Ingelheim GMBH, Biogen, Novartis AG, Medicinova, Inc., Bristol-Myers Squibb Company, Galapagos NV, F. Hoffmann-La Roche AG, Fibro
3 comments
Read more

Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Regional Analysis, Competitive Landscape Forecast to 2023

Idiopathic Pulmonary Fibrosis Treatment is a life-threatening condition of the lungs in which tissues becomes thickened, stiff, and scarred over a long period. The IPF treatment market is driven by various factors such as growing demand for minimally invasive procedures to diagnose and treat different chronic diseases, increasing geriatric population, along with the rising prevalence rates of IPF and other fibrotic diseases. Market Overview The high cost of surgery and the unavailability of proper treatment options are expected to curb the growth of the IPF treatment. The Global  Idiopathic Pulmonary Fibrosis Treatment Market  is expected to register a  CAGR of 12.3%  during the forecast period of 2019 to 2025, with a market value of USD 2,237 million in 2018. The global IPF treatment market is currently dominated by numerous market players. The key players are involved in new product launches and strategic collaborations to strengthen its market position. For instance, in Sept
2 comments
Read more

Chatbots in Healthcare Market Research Report by Top Industry Vendors and Applications Scenario till 2023

Chatbots in Healthcare Market Overview Healthcare chatbots are programs which assist patients with queries. This reduces the burden on the clinical staff and lets them focus on their jobs. Automation of various workflow processes in the healthcare sector is likely to propel the demand for these virtual assistants. The global Chatbots in Healthcare Market is expected to touch USD 316.85 million by 2023 at 21.10% CAGR over the forecast period (2018-2023), as per Market Research Future (MRFR). It stood at USD 100.46 million in 2017. Rise of chronic diseases coupled with lack of medical experts to handle queries are main drivers of the market. For instance, cancer patients used chatbots to gain rapid assistance regarding medication and their adverse effects.  The  Chatbots in Healthcare Market   Free Growth Sample will provide valuable insight with an emphasis on the global market including some of the  major players  such As,  Sensely, Inc. (U.S.), Your.MD (U.K.), Buoy Healt
2 comments
Read more